Crohn’s disease-related ‘gastrocnemius myalgia syndrome’ successfully treated with infliximab: A case report

Abstract

BACKGROUND

Extra-intestinal manifestations in inflammatory bowel diseases (IBD) are frequent and involve virtually all organs. Conversely, the clinical characteristics and course of inflammatory myopathies in IBD remain poorly described and mostly related to orbital myositis. Moreover, alternative therapeutic strategies in non-responder patients to corticosteroid therapy must still be clarified.

CASE SUMMARY

A 33-year-old woman with a history of unclassified colitis presented with acute bilateral calf pain. On admission, her clinical and biological examinations were non-specific. However, magnetic resonance imaging showed bilateral inflammatory changes in gastrocnemius muscles suggestive of myositis. Muscle biopsy confirmed the diagnosis of myositis and demonstrated an inflammatory infiltrate mainly located in the perimysial compartment including lympho-plasmocytic cells with the formation of several granulomatous structures while the endomysium was relatively spared. The combined clinical, biological and histomyopathological findings were concordant with the diagnosis of ‘gastrocnemius myalgia syndrome’ (GMS), a rare disorder associated with Crohn’s disease (CD). Ileocolonoscopy confirmed CD diagnosis and systemic corticosteroids (CS) therapy was started, resulting in a rapid clinical improvement. During CS tapering, however, she experienced a relapse of GMS together with a severe active ileocolitis. Infliximab was started and allowed a sustained remission of both conditions at the latest follow-up (20 mo).

CONCLUSION

The GMS represent a rare CD-associated inflammatory myopathy for which anti-tumour necrosis factor-α therapy might be considered as an effective therapeutic option.

Key Words: Crohn’s disease; Extra-intestinal manifestation; Gastrocnemius myalgia syndrome; Granulomatous myositis; Anti-tumour necrosis factor-α therapy; Case report

Core Tip: Inflammatory myopathies are scarce in the setting of inflammatory bowel diseases (IBD) and could be wrongly attributed to IBD-related osteoarticular manifestations or to medications’ side effects. This case describes a very atypical presentation of myositis restricted to the legs called the ‘gastrocnemius myalgia syndrome’, an entity only described during Crohn’s disease. Its restricted location to the legs as well as normal creatine kinase levels in serum reflecting a predominant interstitial immune reaction are key characteristics in reported cases. Although corticosteroids are often used as first-line therapy, cortico-dependence is not rare and anti-tumour necrosis factor-α agents might represent an effective therapeutic option.

INTRODUCTION

The multi-system nature of inflammatory bowel diseases (IBD) is widely known. The extraintestinal manifestations (EIMs) of IBD are diverse and deferred from IBD diagnosis in a quarter of the cases. It has been estimated that 6% to 47% of patients with IBD experience at least one EIM[1]. The most frequently reported EIMs include peripheral and/or axial arthropathy, cutaneous lesions, ophthalmological immune-inflammatory manifestations and hepatobiliary affections[2]. However, EIMs can involve almost any organ or tissue, and some rare manifestations, such as specific muscular involvement can also occur and might even herald an hidden IBD[3].

The occurrence of muscular involvement in IBD is scarce, and mostly related to orbital myositis, a subtype of orbital pseudotumor principally reported during Crohn’s disease (CD)[4,5]. Myositis affecting the limbs is a much rarer entity, and is mostly localized in the lower extremities, involving the gastrocnemius muscles, a clinical entity designated as “gastrocnemius myalgia syndrome” (GMS)[3]. To date, very little is known about the full spectrum of myositis occurring during the course of IBD.

We hereby report the first CD-associated GMS in a Belgian patient that turned out to be “granulomatous myositis”, an exceptionally rare subtype. In addition, we performed a literature review by searching EMBASE, MEDLINE, Scopus, and the Cochrane Library databases for studies published between January 1, 1970, and July 7, 2021, using the following keywords or MeSH terms: ‘Inflammatory Bowel Diseases’, ‘Crohn’s Disease’, ‘Ulcerative colitis’, ‘Myositis’, ‘Gastrocnemius myalgia syndrome’ and ‘Granulomatous Myositis’. Finally, we discuss the role of anti-tumour necrosis factor (TNF)-α therapy in this specific context.

CASE PRESENTATION

Chief complaints

A 33-year-old woman presented at the emergency department with a 5-d history of isolated tenderness in both calves leading to walking difficulties.

History of present illness

She denied any traumatism but reported a colitis relapse 30 d before her admission which resolved with a short-course of modified-release beclomethasone therapy.

History of past illness

The patient had a history of allergic asthma, Heliobacter pylori gastritis and unclassified colitis. Previous investigations performed during colitis flares did not discriminate a specific IBD pattern concluding in an unclassified colitis. The patient was not taking any chronic medication. Her familial history was not contributive.

Physical examination

Clinical findings on admission included bilateral swelling of both calves which were warm and painful to palpation. Motricity and sensitive perception were preserved. Examination of other muscles, joints and the spine was unremarkable and her abdomen was soft and non-tender.

Laboratory examinations

Initial laboratory investigations showed a C-reactive protein level at 106.6 mg/L (normal range, 0.4-12 mg/L) with mild neutrophilic leukocytosis (8770/mm³, normal range 1900-8000/mm³). Creatinine kinase (CK), aspartate aminotransferase, lactate dehydrogenase and D-dimer serum levels were within reference values. Hemocultures were negative as well as antinuclear, antineutrophil cytoplasmic and anti-saccharomyces cerevisiae antibodies.

Imaging examinations

Ultrasonography of lower limbs revealed a bilateral 5-millimeter-thick edema surrounding gastrocnemius muscles in the absence of vascular abnormality while a magnetic resonance imaging showed marked inflammation of muscles and their fascia in both legs, suggested by a high signal on T2-weighted images and a strong gadolinium enhancement on fat-suppressed T1-weighted images (Figure 1).

Figure 1 Magnetic resonance imaging of the calves in axial and frontal views. A and C: Demonstration of high signal on T2-weighted images in muscles from posterior and lateral compartments of the legs as well as in their surrounding fascia; B: This finding was accentuated on gadolinium-enhanced fat-suppressed T1-weighted images, suggestive of myositis and fasciitis.

Muscular biopsy

A muscular biopsy of the right gastrocnemius revealed a remarkable inflammatory reaction that particularly involved the perimysial compartment. The infiltrate mainly comprised dense lympho-plasmocytic cells with the formation of several granulomatous structures wherein several histiocytes, sometimes multinucleated, were observed (Figure 2A, C and D). Endomysial inflammatory infiltrate was however less remarkable and rather discrete and focal. There was besides a very mild and discrete perivascular affinity for the inflammatory infiltrate but there was no frank/convincing vasculitis in the examined sections (Figure 2B). A few muscle fibers showed suspected myofibrillary disintegration. Immunohistochemical analyses showed an outstanding cohort of CD3 positive cells (with a slight predominance of CD8⁺ over CD4⁺ cells) (Figure 2C and D). Electron microscopy was generally unremarkable and showed rare lipofuscin deposits. Moreover, rare mastocytes were observed.

Figure 2 Biopsy specimen from the right gastrocnemius muscle showing the intense immune-inflammatory reaction. A: This hematoxylin and eosin-stained section shows the granulomatous nature (arrowhead) of this Crohn’s disease-associated skeletal myositis, predominating in the perimysial compartment; B: Discrete and focal immune infiltrates are found in the endomysium and around vascular structures (arrows); C and D: Immunohistochemical staining characterize immune cell-types involved therein: Co-staining for CD3 (brown staining) and CD20 lymphocytes (red staining) shown in C reveals predominance of CD3⁺ lymphocytes over CD20⁺ cells. CD4 and CD8 T cells subtyping shown in D (brown and red staining respectively) further reveals a slight predominance of CD8⁺ over CD4⁺ cells.

FINAL DIAGNOSIS

This histomyopathological affection in this clinical context was concordant with the GMS, a rare disorder classically associated with CD[6]. Moreover, a new ileocolonoscopy was performed during the hospital stay and revealed endoscopic pattern in favor of CD diagnosis, despite the absence of intestinal granuloma on histopathologic examination.

TREATMENT

Considering these results, the patient was started on a prednisone equivalent dose of 1 mg/kg, resulting in a rapid clinical and biochemical remission.

OUTCOME AND FOLLOW-UP

Two months later, the patient experienced intestinal symptoms associated with a recurrence of pain in both legs during corticosteroids (CS) tapering. The ileocolonoscopy performed at that time showed a very severe ileocolitis [CD Endoscopic Index of Severity (CDEIS) scored at 31] with no histopathologic evidence of granuloma for which intravenous methylprednisolone (1 mg/kg for 5 d) and infliximab (5 mg/kg at week 0, 1 and 4) therapies were started to target both muscular and intestinal disease leading to clinical remission of both ileocolitis- and myositis-related symptoms. Oral corticotherapy was then prescribed and slowly tapered while infliximab was continued (5 mg/kg, every 8 wk). Twenty months later, both ileocolitis and myositis were quiescent.

DISCUSSION

Inflammatory myopathies (IM) occurring in the setting of IBD are considered as rare EIMs and have been roughly described in the literature to date[6]. We report the first CD-associated GMS in a Belgian patient that besides turned out to be “granulomatous”. This represents a very exceptional subtype as there has been only two such reported cases. To the best of our knowledge, only 15 cases of GMS are described in the international literature and always occurred in patients with CD (Table 1). Apart from GMS, orbital myositis, which is currently considered as a subtype of idiopathic orbital inflammation, has also been reported in patients with IBD, mainly CD[5]. Few cases of dermatomyositis (DM) and polymyositis have also been described during the course of IBDs and a recent study showed that DM was more frequent in ulcerative colitis patients than CD patients and control subjects[7]. Nevertheless, the true incidence of IM occurring in this context is probably underestimated as myalgia can be confused with joint manifestations or with non-inflammatory muscle disorders (e.g., secondary to hypokalemia or medications) and by the fact that clinicians may rule out myositis’ diagnosis in the absence of CK elevation in serum.

Table 1 Case descriptions of gastrocnemius myalgia syndrome reported in Crohn’s disease.

Ref.	Age (yr)/sex at GMS onset	Initial presentation, time-to-onset	Active CD at time of GMS dx	CK serum level	Biopsy	Treatment	Corticosteroids-dependence (d) or resistance (r)
Ménard et al[8], 1976	44/M	Muscular, 2 mo	No	N	Granulomatous myositis	PDS1 (80 mg/d)	No
Gilliam et al[13], 1981	19/M	Digestive, 6 mo	Yes	N	Necrotizing vasculitis	PDS1 (60 mg/d)	No
Hall et al[10], 1985	32/F	Muscular, 120 mo	Yes	N	Non-granulomatous myositis	5-ASA1, PDS1 (25 mg/d)	No
Drabble and Gani[14], 1992	50/M	Digestive, 168 mo	Yes	N	Not performed	Hydrocortisone1 (400 mg/d), PDS1	No
Disdier et al[11], 1997, Case 1	26/F	Muscular, 48 mo	Yes	N	Necrotizing vasculitis	PDS1 (60 mg/d), CYC1, 5-ASA1	Yes (r)
Disdier et al[11], 1997, Case 2	21/F	Simultaneous	Yes	N	Vasculitis	PDS (1 mg/kg/d), AZA1	Yes (d)
Christopoulos et al[3], 2003	19/F	Simultaneous	Yes	N	Granulomatous myositis	PDS1 (0.5 mg/kg/d)	No
Ullrich et al[15], 2009	25/F	Digestive, 84 mo	Yes	N	Vasculitis	PDS (50 mg/d), AZA, IFX1	Yes (d)
Co et al[16], 2010	15/F	Digestive, 8 mo	Yes	N	Not performed	IFX1	/
Mogul et al[17], 2010	15/M	Digestive, 60 mo	No	N	Non-granulomatous myositis	PDS1 (40 mg/d), MTX1	No
Piette et al[18], 2010	45/M	Simultaneous	Yes	(3-13 × N)	Vasculitis	PDS1 (1 mg/kg/d)	No
Goldshmid et al[19], 2011	24/F	Simultaneous	Yes	(330 U/L)	Not performed	MPDS (100 mg/d), IFX1, AZA1	Yes (d)
Vadala di Prampero et al[20], 2016	26/M	Digestive, 72 mo	Yes	N	Non-granulomatous myositis	PDS (60 mg/d), AZA1 (chronic), Adalimumab1	Yes (d)
Saffar[12], 2017	33/F	Digestive, 120 mo	Yes	N	Not performed	PDS, IFX1	Yes (r)
Osada et al[9], 2018	38/M	Digestive, 3 mo	Yes	N	Non-granulomatous myositis	PDS, AZA1, 5-ASA1	Yes (d)
Current case	33/F	Simultaneous	Yes	N	Granulomatous myositis	MDPS (0.8/kg/d), IFX1	Yes (d)

¹These treatment modalities are those that induced a persistent remission of myositis-related symptoms.

GMS: Gastrocnemius myalgia syndrome; CD: Crohn’s disease; MDPS: Mitochondrial-derived peptides; IFX: Infliximab; ASA: Aminosalicylate; AZA: Azathioprine; PDS: Peroxydisulfate.

The first case of myositis affecting gastrocnemius muscles in CD was reported in 1979 by Ménard et al[8] who described a 44-year-old man with granulomatous myositis localized to the calf occurring two months before CD diagnosis[8]. Since then, several cases have been reported, sharing the classically following features: (1) Calf-limited myalgia revealing localized myositis; (2) Normal serum CK levels; and (3) A high early-response rate to CS therapy[9]. In 2003, this entity was denominated as “GMS” by Christopoulos et al[3], a term adopted in the literature ever since[10]. Most patients developed GMS months or years after the onset of CD but myositis could precede gastrointestinal manifestations by up to 10 years[11]. When CD had been diagnosed before GMS, the intestinal disease was active in most cases at myositis’ diagnosis (Table 1). Other EIMs were associated with GMS in 50% of patients which is in accordance with previous observations that patients who presented an EIM are at higher risk to develop another one[1].

While clinical and biological features in patients with GMS are generally characteristics, histomyopathological findings are rather heterogeneous. In fact, our case is only the third in which granulomatous lesions were observed while all remaining reported cases were characterized by non-granulomatous inflammation (4 cases) or localized vasculitis (5 cases) (Table 1). However, whatever the histopathologic image observed, the inflammatory infiltrate was more often localized in the perimysium and more discrete in the endomysium, probably explaining why most patients with GMS have normal CK values. GMS could therefore represent a form of localized “perimyositis” with no or limited myofiber injury. This observation also suggests that the immune response is directed against connective tissue components or vessels rather than against the myofibers themselves.

Finally, while GMS was initially controlled in this case by oral CS therapy, it ultimately relapsed during tapering. In this context, the presence of a concomitant severe active ileocolitis prompted us to start an anti-TNF-α agent. While CS were the first-line treatment prescribed in almost all cases of GMS, their efficacy, however, was not enduring as 6/16 patients (including ours) relapsed during dose de-escalation (Table 1). Moreover, two other patients were initially refractory to CS[12,13]. Various drugs were used in these corticosteroid-dependent or refractory cases. Anti-TNF-α agents were constantly associated with GMS remission in the six cases where they were introduced, suggesting that the muscular and intestinal affections in this context could share a common pathophysiological mechanism. Importantly, our case represents the first GMS with granulomatous inflammation treated with an anti-TNF-α agent. Further case descriptions and/or case series will be required to ascertain the role of such therapy in this specific context.

CONCLUSION

In conclusion, we report a rare extra-intestinal manifestation of CD, namely a GMS, characterized by a very rarely reported granulomatous perimyositis. The rapid relapse of GMS during CS tapering and the emergence of a severe active ileocolitis prompted the introduction of an anti-TNF-α agent that resulted in persistent clinical remission of both disorders. This might further suggest the effectiveness of such agents in CS-dependent or refractory cases. Finally, physicians should remain aware of the eventual emergence of a such complicating myositis when musculo-skeletal symptoms arise in IBD patients even in the absence of CK elevation.

ACKNOWLEDGEMENTS

We thank Anaïs Boisson (Laboratory of Molecular Immunology, Jules Bordet Institute, Brussels, 1000, Belgium) who performed immunohistochemistry stainings.